title: HBA1C AND MEAN GLUCOSE DERIVED FROM SHORT-TERM CONTINUOUS GLUCOSE MONITORING ASSESSMENT DO NOT CORRELATE IN PATIENTS WITH HBA1C >8.
abstract: OBJECTIVE
  Optimum therapy for patients with diabetes depends on both acute and long-term changes in plasma glucose, generally assessed by glycated hemoglobin (HbA1c) levels. However, the correlation between HbA1c and circulating glucose has not been fully determined. Therefore, we carefully examined this correlation when glucose levels were assessed by continuous glucose monitoring (CGM).
  
  
  METHODS
  Fifty-one patients (70% female, 30% male) were examined; among them were 28 with type 1 diabetes and 23 with type 2 diabetes. Clinically determined HbA1c levels were compared with blood glucose determined by CGM during a short time period.
  
  
  RESULTS
  Changes in HbA1c levels up to 8.0% showed a clear and statistically strong correlation (R = 0.6713; P<.0001) with mean blood glucose levels measured by CGM, similar to that observed in the A1c-derived Average Glucose study in which patients were monitored for a longer period. However, we found no statistical correlation (R = 0.0498; P = .83) between HbA1c and CGM-assessed glucose levels in our patient population when HbA1c was >8.0%.
  
  
  CONCLUSIONS
  Short-term CGM appears to be a good clinical indicator of long-term glucose control (HbA1c levels); however, cautions should be taken while interpreting CGM data from patients with HbA1c levels >8.0%. Over- or underestimation of the actual mean glucose from CGM data could potentially increase the risks of inappropriate treatment. As such, our results indicate that a more accurate analysis of CGM data might be useful to adequately tailor clinical treatments.
  
  
  BACKGROUND
  ADAG = A1c-Derived Average Glucose CGM = continuous glucose monitoring %CV = percent coefficient of variation HbA1c = glycated hemoglobin.
authors.forename: Eijiro
authors.initials: E
authors.lastname: Yamada
authors.forename: Shuichi
authors.initials: S
authors.lastname: Okada
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Claire C
authors.initials: CC
authors.lastname: Bastie
authors.forename: Manu
authors.initials: M
authors.lastname: Vatish
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tagaya
authors.forename: Aya
authors.initials: A
authors.lastname: Osaki
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shimoda
authors.forename: Ryo
authors.initials: R
authors.lastname: Shibusawa
authors.forename: Tsugumichi
authors.initials: T
authors.lastname: Saito
authors.forename: Takashi
authors.initials: T
authors.lastname: Okamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ozawa
authors.forename: Masanobu
authors.initials: M
authors.lastname: Yamada
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human